CJC-1295 references: every figure on this site, traced to its source.

How this reference list is organized

Every quantitative claim in this CJC-1295 console maps to a numbered citation below. The core human pharmacokinetic findings — the 5.8-to-8.1-day half-life, the +7.5-fold basal GH, the +45% IGF-1, the preserved pulse pattern — come from references 1 and 3 ^[1][3]. The preclinical bioconjugation and receptor data come from references 2 and 4 ^[2][4]. The remaining entries cover the proteomic, analytical, synergy, and review literature that situates the compound in its class. Where a study is paywalled, the linked abstract and DOI remain the canonical record.

The human evidence (references 1, 3, 5)

Three human studies carry most of what is reliably known. Teichman 2006 established the pharmacokinetics — the dose-dependent multi-day rise in GH and IGF-1 and the 5.8-to-8.1-day half-life ^[1]. Ionescu/Frohman 2006 established the pulsatility result — basal GH up roughly 7.5-fold and IGF-1 up about 45% at one week, with pulse frequency and amplitude unaltered ^[3]. Sackmann-Sala 2009 added the proteomic dimension, finding reproducible serum-protein shifts that correlated with IGF-1 — candidate biomarkers of axis activation ^[5].

All three are early-phase work in healthy adults. None is a large efficacy or long-term safety trial, and that absence is itself part of the record this site reports ^[1].

The preclinical and class literature (references 2, 4, 6-15)

The preclinical foundation is Jette 2005, which identified CJC-1295 as the lead long-lasting GRF analog and showed the 4-fold GH AUC advantage over unconjugated peptide in rats ^[2], and Alba 2006, which showed once-daily CJC-1295 normalized growth in GHRH-knockout mice ^[4]. The synergy literature behind the ipamorelin pairing — the GHRH-plus-GHRP supra-additive effect, ghrelin potentiation, and differential pulsatile control — is references 8, 9, and 10 ^[8][9][10].

The analytical entries (references 6, 11, 12) document how CJC-1295 and its class are detected, including the LC-MS/MS identification of the compound in a seized preparation ^[6]. References 7 and 13 cover the episodic-versus-continuous GHRH physiology and GHRH-analog wound-healing work ^[7][13]. References 14 and 15 are recent reviews situating GHRH analogs in endocrinology and aging research ^[14][15].